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General Model for estiMatinG Medical and criMinal justice costs 
aMonG Patients witH scHizoPHrenia after release froM jail/Prison
Lin I.1, Muser E.2, Munsell M.1, Benson C.2, Menzin J.1
1Boston Health Economics, Inc., Waltham, MA, USA, 2Janssen Scientific Affairs, LLC, Titusville, 
NJ, USA
Objectives: To develop an economic model that estimates the cost burden of psy-
chiatric relapse and recidivism among patients with schizophrenia after release 
from jail/prison from a US state government perspective. MethOds: A Markov 
state-transition model was developed to estimate the numbers of schizophrenia 
patients newly-released from jail/prison who would experience psychiatric relapse 
and/or arrest and re-incarceration over a period of three years, along with corre-
sponding costs. The model includes three health states: 1) in community, on therapy, 
2) in community, off therapy, and 3) incarcerated. A patient’s probability of psychi-
atric hospitalization increases with treatment discontinuation, and the probability 
of arrest increases with the risk of a psychiatric hospitalization. Data from the US 
Census and Bureau of Justice Statistics were used to estimate the model population. 
Published literature was used to estimate the risks of psychiatric relapse, arrest, 
and direct cost inputs associated with hospitalization, arrest, trial, and incarcera-
tion. Felony and misdemeanor incarceration rate and sentence length data from 
the State of Florida were applied as a base case scenario. The rate of antipsychotic 
treatment following release from jail/prison and annual risk of medication dis-
continuation were varied in sensitivity analyses. Results: Among 34,500 persons 
released from Florida state prison annually, 5,307 were estimated to have schizo-
phrenia. The estimated three-year cumulative direct costs to the state government 
were $21,146,000 and $25,616,000 for criminal justice and psychiatric hospitalization 
costs, respectively ($3,985 per patient criminal justice costs; $4,827 per patient hos-
pitalization costs). An absolute 20% increase in the proportion of patients receiving 
antipsychotic treatment following release from jail/prison decreased total cumu-
lative costs over three years by $588 per patient. cOnclusiOns: The economic 
impact of recidivism and psychiatric relapse among patients with schizophrenia is 
substantial from a state government perspective. This general model can be made 
state-specific by utilizing local criminal justice data sources.
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Trinchero J.1, Haiek D.1, Tannus G.2, Fonseca M.3
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Objectives: It is not known the profile of the children or the economic and social 
impact of autism in Brazil. The support therapy to children with autism includes 
psychologist, speech therapist, and occupational therapy. Antipsychotics are being 
used in autism treatment. We aimed to know the profile of children with autism and 
the social and economic impact of the disease in their families. MethOds: Simple 
Internet survey conducted among Brazilian autism communities during October 
2013. We performed descriptive statistics. All monetary values are in Brazilian reais 
(BRL). Results: We obtained 48 responses. 70.8 % of autism patients were boys. The 
median age was 8 years and 54 % of the patients were between 6 and 10 years. 65 % 
of the diagnoses were made between 2 and 4 years of age. The median number of 
physicians visited to achieve diagnosis was 3, 56% of the children visited 1-3 doctors 
and 23 % had to visit more than 5 doctors. Risperidone was used by 48% of cases 
and main reported side effects were insomnia (10 %), agitation (47 %), anxiety (23 %), 
headache (7 %), and self-reported changes in eating habits (13 %). 28 % of patients 
reported some food allergy. To provide support therapy to children with autism 34 
% of families spend between 500-1500 BRL; 1500 to 2500 (19 %), 2500-3500 (17 %) 
and 2% spend 3500-4500. In 13 % spending was less than 500 and in 15 % spent over 
4500. In 53% of the families the expenditure with support therapy is higher than 
the median household income in Brazil (R$ 1,211.33). cOnclusiOns: Our results 
were in agreement with literature considering gender, age at diagnosis, frequency 
of food allergy and use of antipsychotics. Support therapy for these children can be 
higher than the median household income in Brazil.
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Objectives: To assess the impact of baseline characteristics, including prior year 
adherence and use of paliperidone palmitate (PP), on AP continuity metric perfor-
mance. MethOds: Medicaid health care claims data from five states (2008-2011) 
were used to identify patients 25-64 years of age diagnosed with schizophrenia and 
≥ 1 AP Rx in baseline year 2010 (BY) and in measurement year 2011 (MY). Adherence 
to AP was defined as the percentage with dispensed AP medication covering ≥ 80% 
of a given year. Baseline year characteristics including demographics, health care 
costs, AP treatment and adherence status were evaluated as potential predictive 
factors of MY continuity using multivariate logistic analyses. Two mutually exclusive 
cohorts (patients with any PP claim vs. all other AP patients in BY) were compared 
on continuity measure performance using inverse propensity score weighting (IPW), 
with propensity representing the likelihood of PP treatment based on BY charac-
teristics. Results: In the study population of 12,990 AP users, 48.6% successfully 
achieved the AP continuity criteria in MY. After controlling for other covariates, the 
likelihood of continuity measure success was improved by adherence in BY (odds 
Objectives: To examine the economic burden and health care utilizations of 
depression patients in the U.S. veteran population. MethOds: Patients diagnosed 
with depression were identified (International Classification of Disease, 9th Revision, 
Clinical Modification [ICD-9-CM] diagnosis codes 296.2x, 296.3x, 300.4, 301.13, 309.0x 
and 311.xx) using the Veterans Health Administration (VHA) Medical SAS datasets 
from October 1, 2007 through September 30, 2012. The initial diagnosis date was 
designated as the index date. A comparison cohort was created for patients with-
out a depression diagnosis, using 1:1 propensity score matching to control for age, 
region, gender, index year and baseline Charlson Comorbidity Index score. For the 
comparison cohort, the index date was randomly chosen to minimize selection bias. 
Patients in both cohorts were required to be at least age 18 years, and have continu-
ous medical and pharmacy benefits 1 year pre- and 1 year post-index date. Study 
outcomes (health care costs, utilizations) were compared between the disease and 
comparator cohorts, based on the matched sample. Results: After 1:1 matching, a 
total of 614,093 patients were identified in each group, and baseline characteristics 
were well-balanced. Patients diagnosed with depression were more likely to have 
inpatient stays (12.73% vs. 2.09%, p< 0.0001) and emergency room (ER) (18.64% vs. 
6.24%, p< 0.0001), physician office (99.59% vs. 54.08%, p< 0.0001), outpatient (99.70% 
vs. 54.83%, p< 0.0001) and pharmacy visits (90.49% vs. 52.20%, p< 0.0001). Higher 
all-cause inpatient stay ($4,017 vs. $599, p< 0.0001), ER visit ($199 vs. $55, p< 0.0001), 
physician office visit ($4,034 vs. $1,152, p< 0.0001), total outpatient ($4,477 vs. $1,304, 
p< 0.0001), pharmacy ($724 vs. $327, p< 0.0001) and total health care costs ($9,218 vs. 
$2,230, p< 0.0001) were also observed for depression patients relative to comparator 
patients. cOnclusiOns: During a period of 12 months, VHA patients diagnosed 
with depression reported higher health care utilization and costs than matched 
control patients.
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investiGatinG econoMic risk factors tHat iMPact Mental HealtH 
status of forMer arMy Personnel
Rebeira M.
University of Toronto, Toronto, Canada
Objectives: To understand key economic risk factors that are associated with the 
following mental health conditions for former regular forces personnel who had 
served with the Canadian army. These health conditions include mood disorders, 
depression, anxiety, post-traumatic stress disorder (PTSD) and combined mental 
health status of all four conditions. MethOds: Using different forms of regression 
analysis of cross-sectional data obtained from a survey conducted by Statistics 
Canada in 2010-11 of former army forces personnel. Key risk categories were iden-
tified from economic theory and include educational attainment, military career 
characteristics, behavioural characteristics, income and demographic characteris-
tics. Regression analysis conducted included ordinary-least squared regression, logit 
and probit analysis. In addition, various diagnostic tests were conducted to ensure 
the robustness of econometric models. Results: The results showed that higher-
earning personnel had a significantly lower risk of mental health conditions than 
lower-earning personnel. Obesity significantly increases the risk of mental health 
conditions. Younger former personnel had a significantly greater risk of mental 
health conditions than their older counterparts. Another significant association was 
gender where female personnel showed a greater risk of mental health disorders. 
Deployment for extended periods outside Canada was also shown to be significantly 
associated with increased risk. Rank within the military and the branch of deploy-
ment did not show a significant association with increased risk. The results also 
showed that the higher the educational attainment, the lower the risk of mental 
health conditions though this result was not significant. Significance was set at the 
5% level. cOnclusiOns: This study is the first comprehensive analysis of economic 
risk factors associated with mental health conditions of former army personnel in 
Canada. The results aligned with established economic theory. Additional analysis to 
understand the underlying reasons shown in these results and policy implications 
will be investigated in the presentation.
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Objectives: To describe estimated health resource (HR) and criminal justice (CJ) 
system costs for patients with schizophrenia recently released from incarceration 
that are participating in a clinical trial. MethOds: Interim baseline HR and CJ events 
collected via a resource use questionnaire from a clinical study of individuals with 
schizophrenia recently released from incarceration were analyzed. HR and CJ utiliza-
tion were evaluated for the most recent CJ event prior to study enrollment, the time 
between this CJ event and enrollment, and the year prior to this CJ event (pre-period). 
HR and CJ cost estimates were obtained from administrative claims and published 
literature then applied to the utilization data pro-rated to 365 days. Costs were sum-
marized descriptively using a state government payer perspective and presented in 
2011 US dollars. Results: Mean total cost (n= 422) in the year prior to enrollment 
was $28,631(SD $20,680; Median $23,445). Mean cost of the qualifying CJ event was 
$14,824 (SD $14,846; Median $10,819). The top 3 most frequent CJ qualifying events 
were parole/probation violation, drug charges, and disorderly conduct/vagrancy/pub-
lic intoxication. Average duration of observation for time periods before and after the 
qualifying CJ event was 243 days (SD 103) and 66 days (SD 72), respectively. Estimated 
mean HR cost in the period prior to CJ qualifying event (pre-period) was $2,485 (SD 
$4,959; Median $929), and mean CJ cost was $6,668 (SD $12,401; Median $0). Among 
those with at least one CJ event in the pre-period (n= 183), average CJ cost was $15,376 
(SD $14,870; Median $11,095). Mean HR cost between the CJ event and enrollment was 
$2,030 (SD $3,452; Median $846). cOnclusiOns: From a state government perspec-
tive, mental health related HR and CJ contacts are costly and are potentially avoidable. 
These data can be used to model HR and CJ costs in a population with schizophrenia.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A219
pleted every 6 months, as well as the Subjective Side Effect Rating Scale, assessing 
patient distress over extrapyramidal symptoms, weight gain, sedation and sexual 
dysfunction over the past seven days. A random-effects regression analysis was 
used to estimate the impact of these adverse events on utilities with adjustment 
on disease severity and other potential confounding factors. Results: Our sample 
consisted in 1208 patients with schizophrenia. At baseline, the mean EQ-5D utility 
was 0.73 (0.28), 57.7% of patients reported extrapyramidal symptoms, 46.2% weight 
gain, 46.5% sedation and 27.8% sexual dysfunction. The regression model showed 
that extrapyramidal symptoms, weight gain, sedation and sexual dysfunction were 
associated with reductions in utility of 0.054 (0.008), 0.018 (0.008), 0.021 (0.008) and 
0.032 (0.011) points, respectively. cOnclusiOns: This study shows that side effects 
are associated with significant decrements in EQ-5D utility, especially extrapyrami-
dal symptoms. Additionally, adverse events may have an indirect negative impact 
on quality of life, since they may be associated with reduced treatment adherence, 
and therefore reduced treatment effectiveness.
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tHe association Between residual syMPtoMs of dePression witH 
Mental and PHysical quality of life in Patients wHo Have Been 
treated witH antidePressant Medications
Pawaskar M.1, Supina D.1, Cossrow N.1, Dirks B.1, Witt E.A.2
1Shire, Wayne, PA, USA, 2Kantar Health, Princeton, NJ, USA
Objectives: Examine the association between residual symptoms of depression 
(depressive symptoms still present after 3 months of antidepressant treatment) 
and patient reported mental and physical quality of life. MethOds: A subset of 
patients from the 2012 National Health and Wellness survey (n = 71,157), an annual 
general health survey of US adults, was used in this analysis. Inclusion criteria 
were a diagnosis of depression and treatment with an antidepressant medication 
for at least 3 months (n = 5,354). Residual symptoms were measured via the 9-item 
Personal Health Questionnaire (PHQ-9) depression scale and quality of life was 
measured via the SF-36v2 mental and physical component summary scores (MCS 
and PCS). Inter-relationships among symptoms were assessed using Pearson cor-
relations, and Ordinary Least Squares (OLS) regression was used for MCS and PCS 
analyses. Results: The most common residual symptoms were fatigue (49.6%; 
“Feeling tired or having little energy”) and sleep problems (42.8%; “Trouble falling 
or staying asleep, or sleeping too much”). All residual symptoms were more strongly 
correlated with MCS scores (r = -.37 to -.60) compared with PCS scores (r = -.06 to 
-.26) (p< .01). In the OLS regression models, anhedonia (“Little interest or pleasure in 
doing things”) and sadness (“Feeling down, depressed, or hopeless”) held the strong-
est associations with lower MCS scores (p< .001), whereas fatigue held the strongest 
association with lower PCS scores (p< .001) after controlling for other residual symp-
toms. cOnclusiOns: Residual symptoms of depression persist despite adequate 
duration of antidepressant treatment and are associated with poorer quality of life. 
Anhedonia and sadness were most strongly associated with lower mental quality 
of life while fatigue was most strongly associated with lower physical quality of life.
PMH63
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Objectives: The efficacy of lurasidone in reducing depression symptoms and 
improving functioning among patients with bipolar depression has been previ-
ously demonstrated. This analysis examines the direct and indirect effect (mediated 
through improvement in depression symptoms) of lurasidone in improving patient 
functioning. MethOds: Data from a 6-week, double-blind, placebo-controlled trial 
assessing the effect of treatment [lurasidone (20–60 mg or 80-120 mg) versus pla-
cebo] in bipolar depression was used. Patient functioning was measured using a vali-
dated patient reported outcomes scale, Sheehan Disability Scale (SDS), that assessed 
functioning in work/school, family, and social life (higher scores indicate greater 
disability). Depression symptoms were measured using the 10-item Montgomery-
Asberg Depression Rating Scale (MADRS; higher scores indicate greater severity). 
Path analyses evaluated total effect (β 1), as well as the indirect effect (β 2*β 3) and 
direct effect (β 4) of treatment on SDS change, using standardized beta path coef-
ficients and baseline scores as covariates. The direct effect of treatment on SDS 
change and indirect effects accounting for mediation through MADRS change was 
examined for statistical significance and magnitude. Results: Path analyses (n 
= 258) revealed a moderate total effect for treatment predicting improvement in SDS 
score (β 1= -0.40, p= 0.001). Treatment predicted improvement in MADRS (β 2= -0.33, 
p= 0.009), which subsequently predicted improvement in SDS (β 3= 0.70, p< 0.001; 
indirect effect = -0.23). The direct effect was small yet significant (β 4= -0.17, p= 0.04), 
indicating partial mediation. Indirect and direct effects accounted for 57% and 43% 
of the total effect, respectively. The full mediation model with indirect and direct 
effects explained 61.7% of the variation in the change in SDS scores. cOnclusiOns: 
These analyses show that improvement in patient functioning among patients 
on lurasidone was largely mediated through reduction in depression symptoms. 
Lurasidone also had a small but statistically significant direct effect in improving 
patient functioning that was independent of improvements in depression within 
a 6-week study duration.
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Objectives: This study aimed to determine the validity (construct, known-
groups), reliability (internal consistency), and floor and ceiling effects of the 12 
ratio (OR): 9.42; 95% confidence interval (CI): 8.55-10.39), female sex (OR: 1.11; 95%CI: 
1.01-1.22), age 55-64 (OR: 1.26; 95%CI: 1.09-1.46) relative to age 25-34, and Hispanic 
(OR: 1.37; 95%CI: 1.05-1.81) relative to white. An incremental $10K in BY inpatient 
admission cost was also associated with greater likelihood of success (OR: 1.11; 
95%CI: 1.08-1.15). Accounting for baseline differences between treatment cohorts 
using IPW, PP use was associated with a 26% increase in the likelihood of continuity 
achievement compared to other AP use (OR: 1.26; 95%CI: 1.14-1.39). cOnclusiOns: 
Baseline factors associated with better performance on the HEDIS Continuity of AP 
Medications measure were prior year adherence, use of PP therapy, higher inpatient 
costs, older age, female gender, and Hispanic ethnicity.
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iMPact of atyPical antiPsycHotics use on lonG actinG stiMulants 
Persistence aMonG cHildren and adolescents witH attention 
deficit HyPeractivity disorder
Bali V.1, Kamble P.2, Aparasu R.R.1
1University of Houston, Houston, TX, USA, 2Healthways Inc., Franklin, TN, USA
Objectives: Pediatric Attention Deficit/Hyperactivity Disorder (ADHD) patients are 
usually prescribed combination of psychotropic agents. This study looked at the 
impact of atypical antipsychotic (AAP) use on long acting stimulant (LAS) persis-
tence in children and adolescents with ADHD. MethOds: This study used 4 years 
(January 2004 to December 2007) of IMS LifeLink™ claims data involving 6-16 years 
old youths with ADHD and at least 1 LAS prescription between July 2004 to December 
2006 and continuous eligibility 6 months before and 1 years after the index LAS pre-
scription. Persistence was measured by summing the total number of days a patient 
remained on the index LAS from the index prescription date with allowable gap of 
no more than 30 days. Multivariate Cox proportional hazards regression was used 
to examine the impact of concomitant atypical antipsychotic use on persistence of 
stimulants. Results: The study cohort consisted of 39,981 subjects. Of these, 1,560 
(3.90%) received LAS and AAP polypharmacy and the rest 38,421 (96.10%) received 
LAS monotherapy. Bivariate analyses revealed that concomitant users had longer 
persistence (by 71 days) than the stimulant alone users. Cox proportional hazards 
regression revealed that concomitant atypical antipsychotic use improved LAS per-
sistence by 15% (HR= 0.85, CI= 0.76-0.94) in comparison to the non-users among LAS 
recipients. Other factors such as age, region, season, coexisting mental health condi-
tions, use of co-medications, and general mental health status influenced the LAS 
treatment persistence among children and adolescents with ADHD. cOnclusiOns: 
Use of atypical antipsychotics improved LAS treatment persistence in children and 
adolescents with ADHD. Various patient, clinical and treatment factors were associ-
ated with the LAS treatment persistence in ADHD youths. Understanding of these 
factors can help to improve persistence to LAS treatment.
PMH60
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Objectives: The aim of this study was to determine the impact of antidepressant 
adherence on health-related quality of life and life satisfaction in a representative 
community sample of older adults. MethOds: The data were obtained from the 
ESA (Étude sur la Santé mentale des Aînés) Services study that included a large 
sample of older adults (n= 1809) aged 65 years and over who consulted and were 
recruited in a primary care practices. HRQOL was measured using the EuroQOL-5D 
which assessed utility values, from the general population perspective and the 
EQ-Visual Analog Scale (EQ-VAS) was used to measure self-reported health sta-
tus from the patient perspective. The CASP was used to measure life satisfaction. 
Common mental disorders were based on DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition) criteria. Antidepressant use was obtained from 
administrative databases. A 4 level dummy variable was constructed to consider the 
presence of depression/anxiety (MD) and antidepressant use (MD X AD). Adherence 
to antidepressant was measured using the medication possession ratio (MPR ≥ 
80%). Multivariate linear regression models were used to study HRQOL and life 
satisfaction as a function of depression/anxiety X antidepressant use (MD X AD) 
controlling for antidepressant use, the presence of chronic and physical disorders 
and other socio-demographic factors. Results: HRQOL measured by the EuroQOL 
was significantly associated with age, cognitive impairment and the presence of 
depression. Self-reported health status measured by the EQ-VAS was associated 
with age, number of chronic illnesses, cognitive impairment. The CASP was associ-
ated with age, and PTSD. Antidepressant use was associated with a lower HRQOL 
and a lower life satisfaction. cOnclusiOns: The study showed that the determi-
nants associated with HRQOL and life satisfaction from the patient and general 
population perspective differs. Future studies should focus on determining other 
factors that influence HRQOL and life satisfaction in older adults.
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utility decreMents associated witH treatMent-related adverse 
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Objectives: Several studies have estimated health state utilities for patients 
with schizophrenia according to disease stage. However, the quality of life of these 
patients is also largely dependent on treatment-related adverse events, and there 
is paucity of data on utilities associated with those adverse events. The objective 
of this study was to estimate utility decrements associated with treatment-related 
adverse events in patients with schizophrenia, using data from an observational 
study. MethOds: We used data from EuroSC, a multicenter 2-year cohort study 
conducted in France, England and Germany. The EQ-5D questionnaire was com-
